Evidence map›Paper›PMID 32381042›Full record

ArticleRadiation oncology (London, England)2020

Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer.

Lien-Chun Lin, Guo-Liang Jiang, Nitin Ohri, Zheng Wang, Jiade J Lu, Madhur Garg, Chandan Guha, Xiaodong Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Lien-Chun LinDepartment of Medical Physics, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 4365 Kangxin Road, Shanghai, 201318, China.
Guo-Liang JiangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Nitin OhriDepartment of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.
Zheng WangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Jiade J LuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Madhur GargDepartment of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.
Chandan GuhaDepartment of Radiation Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA. cguha@montefiore.org.
Xiaodong WuDepartment of Medical Physics, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 4365 Kangxin Road, Shanghai, 201318, China. drxiaodongwu@yahoo.com.
Fudan University Shanghai Cancer Center · CNAlbert Einstein College of Medicine · USMontefiore Medical Center · US

Funding

STATISTICAL ANALYSIS OF CANCER IN ATOMIC BOMB SURVIVORSR01CA051007 · NCI · OREGON STATE UNIVERSITY · PI PIERCE, DONALD A · 1990 to 1992
–
NCI NIH HHS BAA-N01CM51007-51
6 · The paper itself

Abstract

objectiveTo identify a safe carbon ion radiotherapy (CIRT) regimen for patients with locally advanced pancreatic cancer (LAPC).

methodsWe generated treatment plans for 13 consecutive, unselected patients who were treated for LAPC with CIRT at our center using three dose and fractionation schedules: 4.6 GyRBE × 12, 4.0 GyRBE × 14, and 3.0 GyRBE × 17. We tested the ability to meet published dose constraints for the duodenum, stomach, and small bowel as a function of dose schedule and distance between the tumor and organs at risk.

resultsUsing 4.6 GyRBE × 12 and 4.0 GyRBE × 14, critical (high-dose) constraints could only reliably be achieved when target volumes were not immediately adjacent to organs at risk. Critical constraints could be met in all cases using 3.0 GyRBE × 17. Low-dose constraints could not uniformly be achieved using any dose schedule.

conclusionWhile selected patients with LAPC may be treated safely with a CIRT regimen of 4.6 GyRBE × 12, our dosimetric analyses indicate that a more conservative schedule of 3.0 GyRBE × 17 may be required to safely treat a broader population of LAPC patients, including those with large tumors and tumors that approach gastrointestinal organs at risk. The result of this work was used to guide an ongoing clinical trial.

Indexed as

Dose Fractionation, RadiationRadiometryAdultAgedFemaleHeavy Ion RadiotherapyHumansMaleMiddle AgedOrgans at RiskPancreatic NeoplasmsRadiotherapy Planning, Computer-AssistedCarbon ionPancreatic cancerRadiotherapy

Identifiers

PMID32381042
PMCPMC7204055
OpenAlexW3020993221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.